|
1
|
Donepudi MS, Kondapalli K, Amos SJ and
Venkanteshan P: Breast cancer statistics and markers. J Cancer Res
Ther. 10:506–511. 2014.PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLoBoCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao
G, Joseph BK, Rosen C and Shi YE: Identification of a breast
cancer-specific gene, BCSG1, by direct differential cDNA
sequencing. Cancer Res. 57:759–764. 1997.PubMed/NCBI
|
|
4
|
Wu K, Weng Z, Tao Q, Lin G, Wu X, Qian H,
Zhang Y, Ding X, Jiang Y and Shi YE: Stage-specific expression of
breast cancer-specific gene gamma-synuclein. Cancer Epidemiol
Biomarkers Prev. 12:920–925. 2003.PubMed/NCBI
|
|
5
|
Bruening W, Giasson BI, Klein-Szanto AJ,
Lee VM, Trojanowski JQ and Godwin AK: Synucleins are expressed in
the majority of breast and ovarian carcinomas and in preneoplastic
lesions of the ovary. Cancer. 88:2154–2163. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jia T, Liu YE, Liu J and Shi YE:
Stimulation of breast cancer invasion and metastasis by synuclein
gamma. Cancer Res. 59:742–747. 1999.PubMed/NCBI
|
|
7
|
Pan ZZ, Bruening W, Giasson BI, Lee VM and
Godwin AK: Gamma-synuclein promotes cancer cell survival and
inhibits stress- and chemotherapy drug-induced apoptosis by
modulating MAPK pathways. J Biol Chem. 277:35050–35060. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh VK, Zhou Y, Marsh JA, Uversky VN,
Forman-Kay JD, Liu J and Jia Z: Synuclein-gamma targeting peptide
inhibitor that enhances sensitivity of breast cancer cells to
antimicrotubule drugs. Cancer Res. 67:626–633. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou Y, Inaba S and Liu J: Inhibition of
synuclein-gamma expression increases the sensitivity of breast
cancer cells to paclitaxel treatment. Int J Oncol. 29:289–295.
2006.PubMed/NCBI
|
|
10
|
Naldini L: Lentiviruses as gene transfer
agents for delivery to non-dividing cells. Curr Opin Biotechnol.
9:457–463. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vodicka MA: Determinants for lentiviral
infection of non-dividing cells. Somat Cell Mol Genet. 26:35–49.
2001. View Article : Google Scholar
|
|
12
|
Cockrell AS and Kafri T: Gene delivery by
lentivirus vectors. Mol Biotechnol. 36:184–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li MJ and Rossi JJ: Lentiviral vector
delivery of recombinant small interfering RNA expression cassettes.
Methods Enzymol. 392:218–226. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dropulić B: Lentiviral vectors: Their
molecular design, safety, and use in laboratory and preclinical
research. Hum Gene Ther. 22:649–657. 2011. View Article : Google Scholar
|
|
15
|
Diederichs S, Jung S, Rothenberg SM,
Smolen GA, Mlody BG and Haber DA: Coexpression of argonaute-2
enhances RNA interference toward perfect match binding sites. Proc
Natl Acad Sci USA. 105:9284–9289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stovall DB, Wan M, Zhang Q, Dubey P and
Sui G: DNA vector-based RNA interference to study gene function in
cancer. J Vis Exp. 64:e41292012.
|
|
18
|
Sui G, Soohoo C, Affar B, Gay F and Shi Y,
Forrester WC and Shi Y: A DNA vector-based RNAi technology to
suppress gene expression in mammalian cells. Proc Natl Acad Sci
USA. 99:5515–5520. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C,
Wang L, Zhao W, Jiang JD and Liu J: Loss of epigenetic control of
synuclein-gamma gene as a molecular indicator of metastasis in a
wide range of human cancers. Cancer Res. 65:7635–7643. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lavedan C, Leroy E, Dehejia A, Buchholtz
S, Dutra A, Nussbaum RL and Polymeropoulos MH: Identification,
localization and characterization of the human gamma-synuclein
gene. Hum Genet. 103:106–112. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang
B, Zhou Y, Xue R, Luo C, Wang L, et al: Abnormal activation of the
synuclein-gamma gene in hepatocellular carcinomas by epigenetic
alteration. Int J Oncol. 28:1081–1088. 2006.PubMed/NCBI
|
|
23
|
Zhou CQ, Liu S, Xue LY, Wang YH, Zhu HX,
Lu N and Xu NZ: Downregulation of gamma-synuclein in human
esophageal squamous cell carcinoma. World J Gastroenterol.
9:1900–1903. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu C, Guo J, Qu L, Bing D, Meng L, Wu J
and Shou C: Applications of novel monoclonal antibodies specific
for synu-clein-gamma in evaluating its levels in sera and cancer
tissues from colorectal cancer patients. Cancer Lett. 269:148–158.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Linhart W, Briem D, Amling M, Rueger JM
and Windolf J: Mechanical failure of porous hydroxyapatite ceramics
7.5 years after implantation in the proximal tibia. Unfallchirurg.
107:154–157. 2004.In German. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iwaki H, Kageyama S, Isono T, Wakabayashi
Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, et
al: Diagnostic potential in bladder cancer of a panel of tumor
markers (calreticulin, gamma-synuclein, and
catechol-O-meth-yltransferase) identified by proteomic analysis.
Cancer Sci. 95:955–961. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fung KM, Rorke LB, Giasson B, Lee VM and
Trojanowski JQ: Expression of alpha-, beta-, and gamma-synuclein in
glial tumors and medulloblastomas. Acta Neuropathol. 106:167–175.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo J, Shou C, Meng L, Jiang B, Dong B,
Yao L, Xie Y, Zhang J, Chen Y, Budman DR, et al: Neuronal protein
synuclein gamma predicts poor clinical outcome in breast cancer.
Int J Cancer. 121:1296–1305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang Y, Liu YE, Goldberg ID and Shi YE:
Gamma synuclein, a novel heat-shock protein-associated chaperone,
stimulates ligand-dependent estrogen receptor alpha signaling and
mammary tumorigenesis. Cancer Res. 64:4539–4546. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang Y, Liu YE, Lu A, Gupta A, Goldberg
ID, Liu J and Shi YE: Stimulation of estrogen receptor signaling by
gamma synuclein. Cancer Res. 63:3899–3903. 2003.PubMed/NCBI
|
|
31
|
Gupta A, Inaba S, Wong OK, Fang G and Liu
J: Breast cancer-specific gene 1 interacts with the mitotic
checkpoint kinase BubR1. Oncogene. 22:7593–7599. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inaba S, Li C, Shi YE, Song DQ, Jiang JD
and Liu J: Synuclein gamma inhibits the mitotic checkpoint function
and promotes chromosomal instability of breast cancer cells. Breast
Cancer Res Treat. 94:25–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He J, Xie N, Yang J, Guan H, Chen W, Wu H,
Yuan Z, Wang K, Li G, Sun J, et al: siRNA-mediated suppression of
Synuclein γ inhibits MDA-MB-231 cell migration and proliferation by
downregulating the phosphorylation of AKT and ERK. J Breast Cancer.
17:200–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berns K, Hijmans EM, Mullenders J,
Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M,
Nijkamp W, Weigelt B, et al: A large-scale RNAi screen in human
cells identifies new components of the p53 pathway. Nature.
428:431–437. 2004. View Article : Google Scholar : PubMed/NCBI
|
